CTRI/2019/08/020680已完成3 期
Phase-III Clinical Trial with an Intravasal Injectable Male Contraceptive â?? RISUG® - RISUG
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 303
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Age at the time of induction to be in the range 25 - 40 years
- •2. Have two or more normal healthy living children
- •3. Be in good health
- •4. Normal reproductive system and semen parameters (determined by clinical examination and laboratory investigations)
- •5. Wife healthy
- •6. Wife not pregnant at the time of induction of the male into the programme (pregnancy to be excluded by menstrual history, clinical examination and if necessary pregnancy test)
- •7. Wife has not undergone sterilization operation
- •8. In case wife has an intrauterine device she should agree to removal of the IUD when the male partner is inducted into the programme.
- •9. The couple should agree to avoid the use of any contraceptives other than what is advised during the study and in case of conception they should be prepared to undergo Medical Termination of Pregnancy.
- •10. Couple willing to follow the follow up schedule and will undergo all the clinical and laboratory examinations
- •11. For convenience in follow-up, as far as possible the subjects are to be taken from areas close to the trial centre.
排除标准
- •1. Sexually transmitted disease in either partner
- •2. Impotence
- •3. Any psychiatric disorders like anxiety problem
- •4. Chronic pelvic infection or cervical carcinoma of wife
- •5. Diabetes Mellitus
- •6. Any pathology including diseases, which may interfere with the action of the contraceptive agent, induce complications or introduce variables, which may bring in ambiguities in the interpretation of the observations. For example azoospermia or oligozoospermia, cryptorchidism, testicular atrophy, testicular tumors, epididymo-orchitis, cysts and spermatocele related to the epididymis, varicocele, palpably hypertrophied vas deferens, any indications of tuberculosis of the vas deferens etc.
- •7. Pre-existing vaginitis, cervicitis and cervical dysplasia may be wrongly attributed to such an implantation of the polymer into the female system. Vaginitis, cervicitis and cervical dysplasia are to be treated but those with cervical carcinoma in situ and advanced grades of carcinoma are to be excluded.
- •8. The male partners of the women having tuberculosis of the reproductive organs, fibroid and other gynecological problems, which may later affect the pregnancy, also have to be eliminated.
- •9. Wife is not willing to undergo periodic pregnancy test if advised.
研究者
相似试验
尚未招募
1 期
Mesenchymal Stem Cell Therapy For Covid 19CTRI/2020/08/027043eurogen Brain and Spine Institute
已完成
不适用
A randomised phase III study of intravenous (i.v.) zoledronate (administered for 12 versus 36 months) as an adjunct to standard therapies in the treatment of multiple myelomaMultiple myeloma and malignant plasma cell neoplasmsMultiple myelomaCancerISRCTN23172547Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (Netherlands)407
已完成
3 期
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients with Unresectable Hepatocellular Carcinoma (HCC).liver cancer10019815hepatocellular carcinomaNL-OMON50334Biocompatibles UK Ltd.38
已完成
1 期
A clinical trial of intra-arterial infusion chemotherapy with cisplatin for head and neck cancerHead and neck squamous cell carcinomaJPRN-UMIN000017656Department of Radiology Mie University Graduate School of Medicine18
招募中
2 期
Clinical Trial on the Use of Cell Therapy in the Treatment of Patients With Amyotrophic Lateral Sclerosis (TCIM-ELAII)2023-506215-17-00Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia100
